Brokers Set Expectations for Edesa Biotech FY2026 Earnings

Key Points

• Brookline Capital Markets lowered its FY2026 EPS estimate for Edesa Biotech to a loss of $1.98 per share from $1.75, while maintaining a “Strong-Buy” rating. The consensus estimate is a $1.66 loss per share.
• Edesa reported a quarterly loss of $0.60 per share, missing analyst expectations of a $0.44 loss. Analysts remain divided, with ratings ranging from “Strong Buy” to “Strong Sell,” though the overall consensus is “Moderate Buy” with a $5.00 target price.
• The stock opened at $5.65 and has gained 5.6%, but remains well below its 50-day and 200-day moving averages. Institutional ownership stands at 5.5%, led by a nearly $2.95 million position acquired by Perceptive Advisors.

Edesa Biotech, Inc. (NASDAQ:EDSA - Free Report) - Stock analysts at Brookline Capital Markets cut their FY2026 earnings per share estimates for shares of Edesa Biotech in a research report issued to clients and investors on Friday, August 14th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of ($1.98) per share for the year, down from their previous estimate of ($1.75). Brookline Capital Markets has a "Strong-Buy" rating on the stock. The consensus estimate for Edesa Biotech's current full-year earnings is ($1.66) per share. Brookline Capital Markets also issued estimates for Edesa Biotech's Q4 2026 earnings at ($0.57) EPS, FY2027 earnings at ($2.46) EPS, FY2028 earnings at ($2.92) EPS, FY2029 earnings at ($2.37) EPS and FY2030 earnings at ($1.26) EPS.

Several other equities research analysts have also recently weighed in on EDSA. Wall Street Zen cut shares of Edesa Biotech from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Edesa Biotech in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Edesa Biotech Stock Up 5.6%

Shares of NASDAQ EDSA opened at $5.65 on Tuesday. The firm's 50-day simple moving average is $6.29 and its 200 day simple moving average is $6.43. The company has a market cap of $54.43 million, a price-to-earnings ratio of -3.34 and a beta of 1.08. Edesa Biotech has a 12-month low of $0.72 and a 12-month high of $20.32.

Edesa Biotech (NASDAQ:EDSA - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.16).

Hedge Funds Weigh In On Edesa Biotech

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Susquehanna International Group LLP acquired a new stake in Edesa Biotech during the 3rd quarter worth $36,000. State Street Corp acquired a new position in shares of Edesa Biotech in the 4th quarter valued at $27,000. Diadema Partners LP bought a new position in shares of Edesa Biotech in the 4th quarter worth $77,000. DRW Securities LLC bought a new position in shares of Edesa Biotech in the 4th quarter worth $191,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Edesa Biotech during the first quarter worth $2,946,000. 5.50% of the stock is owned by institutional investors.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa's approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa's pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source